Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
Crossref DOI link: https://doi.org/10.1007/s00280-014-2509-6
Published Online: 2014-06-15
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Katopodis, O.
Souglakos, J.
Stathopoulos, E.
Christopoulou, A.
Kontopodis, E.
Kotsakis, A.
Kalbakis, K.
Kentepozidis, N.
Polyzos, A.
Hatzidaki, D.
Georgoulias, V.
Text and Data Mining valid from 2014-06-15